Heartseed
Near-clinical-stage biotech company developing iPSC-derived highly purified ventricular cardiomyocytes for heart failure.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD252m (Public information from May 2023)
Tokyo Japan (HQ)
Authorizing premium user...